JP2018504416A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018504416A5 JP2018504416A5 JP2017539224A JP2017539224A JP2018504416A5 JP 2018504416 A5 JP2018504416 A5 JP 2018504416A5 JP 2017539224 A JP2017539224 A JP 2017539224A JP 2017539224 A JP2017539224 A JP 2017539224A JP 2018504416 A5 JP2018504416 A5 JP 2018504416A5
- Authority
- JP
- Japan
- Prior art keywords
- tyrosine kinase
- pharmaceutical composition
- kinase inhibitor
- subject
- low dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 48
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 48
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 21
- 230000026731 phosphorylation Effects 0.000 claims description 21
- 238000006366 phosphorylation reaction Methods 0.000 claims description 21
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 21
- 230000002159 abnormal effect Effects 0.000 claims description 15
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 12
- 102100021270 Myelin protein zero-like protein 1 Human genes 0.000 claims description 12
- 229960002448 dasatinib Drugs 0.000 claims description 12
- 230000004217 heart function Effects 0.000 claims description 12
- -1 semananib Chemical compound 0.000 claims description 12
- 108050004033 Myelin protein zero-like protein 1 Proteins 0.000 claims description 11
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 claims description 8
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 8
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 8
- 229960001507 ibrutinib Drugs 0.000 claims description 8
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 8
- 102000009076 src-Family Kinases Human genes 0.000 claims description 8
- 108010087686 src-Family Kinases Proteins 0.000 claims description 8
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 208000002330 Congenital Heart Defects Diseases 0.000 claims description 6
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 claims description 6
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 6
- 208000028831 congenital heart disease Diseases 0.000 claims description 6
- 210000005003 heart tissue Anatomy 0.000 claims description 6
- 108091007466 transmembrane glycoproteins Proteins 0.000 claims description 6
- WUPXZZWTHIZICK-UHFFFAOYSA-N 1-[2-[4-[4-amino-5-(3-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenyl]ethyl]piperidin-4-ol Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(C=3C=CC(CCN4CCC(O)CC4)=CC=3)C=2)=C1 WUPXZZWTHIZICK-UHFFFAOYSA-N 0.000 claims description 4
- MVWATCATLSSVBH-UHFFFAOYSA-N 1-[4-[2-[4-[(6-chloro-[1,3]dioxolo[4,5-b]pyridin-7-yl)amino]-5-propan-2-yloxyquinazolin-7-yl]oxyethyl]piperazin-1-yl]ethanone Chemical compound C=1C2=NC=NC(NC=3C(=CN=C4OCOC4=3)Cl)=C2C(OC(C)C)=CC=1OCCN1CCN(C(C)=O)CC1 MVWATCATLSSVBH-UHFFFAOYSA-N 0.000 claims description 4
- UHIZYQVRKSWIFO-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-[3-[3-[(3-phenylphenyl)methyl]triazol-4-yl]phenyl]pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(C=CC=2)C=2N(N=NC=2)CC=2C=C(C=CC=2)C=2C=CC=CC=2)N=C1C1=CC=C(Cl)C=C1 UHIZYQVRKSWIFO-UHFFFAOYSA-N 0.000 claims description 4
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 claims description 4
- XRYJULCDUUATMC-CYBMUJFWSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 XRYJULCDUUATMC-CYBMUJFWSA-N 0.000 claims description 4
- BLQYVHBZHAISJM-CMDGGOBGSA-N 6-(4-methylpiperazin-1-yl)-n-(5-methyl-1h-pyrazol-3-yl)-2-[(e)-2-phenylethenyl]pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1=CC(NC=2NN=C(C)C=2)=NC(\C=C\C=2C=CC=CC=2)=N1 BLQYVHBZHAISJM-CMDGGOBGSA-N 0.000 claims description 4
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 4
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 claims description 4
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 4
- MCAHMSDENAOJFZ-UHFFFAOYSA-N Herbimycin A Natural products N1C(=O)C(C)=CC=CC(OC)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 4
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 4
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 4
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims description 4
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims description 4
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims description 4
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims description 4
- 239000002138 L01XE21 - Regorafenib Substances 0.000 claims description 4
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims description 4
- 206010029748 Noonan syndrome Diseases 0.000 claims description 4
- IIXHQGSINFQLRR-UHFFFAOYSA-N Piceatannol Natural products Oc1ccc(C=Cc2c(O)c(O)c3CCCCc3c2O)cc1O IIXHQGSINFQLRR-UHFFFAOYSA-N 0.000 claims description 4
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 4
- 239000004012 Tofacitinib Substances 0.000 claims description 4
- 230000001594 aberrant effect Effects 0.000 claims description 4
- 229960001686 afatinib Drugs 0.000 claims description 4
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 4
- 229960003005 axitinib Drugs 0.000 claims description 4
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 4
- 229960003736 bosutinib Drugs 0.000 claims description 4
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims description 4
- 229960001292 cabozantinib Drugs 0.000 claims description 4
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims description 4
- 230000009787 cardiac fibrosis Effects 0.000 claims description 4
- 210000004413 cardiac myocyte Anatomy 0.000 claims description 4
- 229960002412 cediranib Drugs 0.000 claims description 4
- 229960001602 ceritinib Drugs 0.000 claims description 4
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 claims description 4
- 229960005061 crizotinib Drugs 0.000 claims description 4
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims description 4
- 229960002465 dabrafenib Drugs 0.000 claims description 4
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims description 4
- 229960001433 erlotinib Drugs 0.000 claims description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 4
- 229960005167 everolimus Drugs 0.000 claims description 4
- 229960002584 gefitinib Drugs 0.000 claims description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 4
- MCAHMSDENAOJFZ-BVXDHVRPSA-N herbimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O MCAHMSDENAOJFZ-BVXDHVRPSA-N 0.000 claims description 4
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 claims description 4
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims description 4
- 229950010895 midostaurin Drugs 0.000 claims description 4
- 210000003365 myofibril Anatomy 0.000 claims description 4
- WPOXAFXHRJYEIC-UHFFFAOYSA-N n-(2-chloro-5-methoxyphenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine Chemical compound COC1=CC=C(Cl)C(NC=2C3=CC(OC)=C(OCC4CCN(C)CC4)C=C3N=CN=2)=C1 WPOXAFXHRJYEIC-UHFFFAOYSA-N 0.000 claims description 4
- 229950008835 neratinib Drugs 0.000 claims description 4
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims description 4
- 230000008520 organization Effects 0.000 claims description 4
- CDRPUGZCRXZLFL-OWOJBTEDSA-N piceatannol Chemical compound OC1=CC(O)=CC(\C=C\C=2C=C(O)C(O)=CC=2)=C1 CDRPUGZCRXZLFL-OWOJBTEDSA-N 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 4
- 229960004836 regorafenib Drugs 0.000 claims description 4
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 claims description 4
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims description 4
- 229960000215 ruxolitinib Drugs 0.000 claims description 4
- 229960002930 sirolimus Drugs 0.000 claims description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 4
- 229960003787 sorafenib Drugs 0.000 claims description 4
- 229960001796 sunitinib Drugs 0.000 claims description 4
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 229960000235 temsirolimus Drugs 0.000 claims description 4
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims description 4
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 4
- 229960001350 tofacitinib Drugs 0.000 claims description 4
- HJQILFPVRNHTIG-UHFFFAOYSA-N tolimidone Chemical compound CC1=CC=CC(OC2=CNC(=O)N=C2)=C1 HJQILFPVRNHTIG-UHFFFAOYSA-N 0.000 claims description 4
- 229960004066 trametinib Drugs 0.000 claims description 4
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960000241 vandetanib Drugs 0.000 claims description 4
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 4
- 229960003862 vemurafenib Drugs 0.000 claims description 4
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 4
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 3
- 229950009919 saracatinib Drugs 0.000 claims description 3
- OUKYUETWWIPKQR-UHFFFAOYSA-N saracatinib Chemical compound C1CN(C)CCN1CCOC1=CC(OC2CCOCC2)=C(C(NC=2C(=CC=C3OCOC3=2)Cl)=NC=N2)C2=C1 OUKYUETWWIPKQR-UHFFFAOYSA-N 0.000 claims description 3
- 108091005990 tyrosine-phosphorylated proteins Proteins 0.000 claims description 3
- 206010067380 Costello Syndrome Diseases 0.000 claims description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims description 2
- 239000002137 L01XE24 - Ponatinib Substances 0.000 claims description 2
- 208000005101 LEOPARD Syndrome Diseases 0.000 claims description 2
- 206010062901 Multiple lentigines syndrome Diseases 0.000 claims description 2
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims description 2
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims description 2
- 208000010708 Noonan syndrome with multiple lentigines Diseases 0.000 claims description 2
- 208000014104 capillary malformation-arteriovenous malformation syndrome Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229960002411 imatinib Drugs 0.000 claims description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960000639 pazopanib Drugs 0.000 claims description 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims description 2
- 229960001131 ponatinib Drugs 0.000 claims description 2
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 238000000034 method Methods 0.000 description 18
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562107553P | 2015-01-26 | 2015-01-26 | |
| US62/107,553 | 2015-01-26 | ||
| US201562250052P | 2015-11-03 | 2015-11-03 | |
| US62/250,052 | 2015-11-03 | ||
| PCT/US2016/014882 WO2016123086A1 (en) | 2015-01-26 | 2016-01-26 | Compositions and methods of using tyrosine kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020200158A Division JP2021050218A (ja) | 2015-01-26 | 2020-12-02 | チロシンキナーゼ阻害剤を用いる組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018504416A JP2018504416A (ja) | 2018-02-15 |
| JP2018504416A5 true JP2018504416A5 (enExample) | 2019-02-21 |
| JP6854766B2 JP6854766B2 (ja) | 2021-04-07 |
Family
ID=56544226
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539224A Active JP6854766B2 (ja) | 2015-01-26 | 2016-01-26 | チロシンキナーゼ阻害剤を用いる組成物および方法 |
| JP2020200158A Pending JP2021050218A (ja) | 2015-01-26 | 2020-12-02 | チロシンキナーゼ阻害剤を用いる組成物および方法 |
| JP2023015070A Pending JP2023052878A (ja) | 2015-01-26 | 2023-02-03 | チロシンキナーゼ阻害剤を用いる組成物および方法 |
| JP2025005945A Pending JP2025061369A (ja) | 2015-01-26 | 2025-01-16 | チロシンキナーゼ阻害剤を用いる組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020200158A Pending JP2021050218A (ja) | 2015-01-26 | 2020-12-02 | チロシンキナーゼ阻害剤を用いる組成物および方法 |
| JP2023015070A Pending JP2023052878A (ja) | 2015-01-26 | 2023-02-03 | チロシンキナーゼ阻害剤を用いる組成物および方法 |
| JP2025005945A Pending JP2025061369A (ja) | 2015-01-26 | 2025-01-16 | チロシンキナーゼ阻害剤を用いる組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US10471059B2 (enExample) |
| EP (2) | EP4653015A2 (enExample) |
| JP (4) | JP6854766B2 (enExample) |
| CN (2) | CN113244399A (enExample) |
| CA (1) | CA2974958A1 (enExample) |
| HK (1) | HK1245678A1 (enExample) |
| MX (2) | MX2017009643A (enExample) |
| WO (1) | WO2016123086A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018134254A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CN106943595A (zh) * | 2017-03-30 | 2017-07-14 | 福州大学 | Src/Abl抑制剂作为预防或治疗辐射损伤药物的应用 |
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| US20210196714A1 (en) * | 2018-06-18 | 2021-07-01 | Duke University | Compositions and methods for treating disorders characterized with aberrant ras/mapk signaling |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
| ES2994095T3 (en) * | 2019-02-27 | 2025-01-17 | Astrazeneca Ab | Saracatinib for use in the treatment of idiopathic pulmonary fibrosis |
| WO2021119525A1 (en) * | 2019-12-11 | 2021-06-17 | Tiaki Therapeutics Inc. | Shp1 and shp2 inhibitors and their methods of use |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| US20240075031A1 (en) * | 2020-12-07 | 2024-03-07 | Hht Foundation International, Inc. | Method of treating hereditary hemorrhagic telangiectasia using pazopanib |
| WO2023127012A1 (ja) * | 2021-12-27 | 2023-07-06 | 国立研究開発法人理化学研究所 | 動脈瘤の治療及び／又は予防のための医薬組成物、動脈瘤の診断補助方法、並びに動脈瘤治療薬の評価方法 |
| EP4507690A1 (en) * | 2022-03-18 | 2025-02-19 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Combination of dasatinib and lovastatin for use in methods for the treatment of cardiac fibrosis |
| CN116832040A (zh) * | 2023-06-12 | 2023-10-03 | 北京市心肺血管疾病研究所 | 细胞周期蛋白依赖性激酶抑制剂在治疗射血分数保留型心力衰竭中的应用 |
| WO2025031474A1 (en) * | 2023-08-10 | 2025-02-13 | Insilico Medicine Ip Limited | Method and medicament for treating endometriosis |
| WO2025111752A1 (zh) * | 2023-11-27 | 2025-06-05 | 中山大学 | 以Lck/Fyn介导STAT3磷酸化为靶点的阻断剂和生物材料的用途 |
| WO2025170008A1 (ja) * | 2024-02-07 | 2025-08-14 | 国立大学法人京都大学 | 成熟心筋細胞の製造方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6355786B1 (en) * | 1998-10-30 | 2002-03-12 | Vanderbilt University | Purified and isolated protein zero related (PZR) and therapeutic and screening methods using same |
| CA2388343A1 (en) * | 1999-11-12 | 2001-05-17 | Mark Steven Marshall | Methods for inhibiting neurofibromatosis type 1 (nf1) |
| CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
| WO2006029319A2 (en) | 2004-09-09 | 2006-03-16 | The General Hospital Corporation | Modulating phosphatase activity in cardiac cells |
| CA2614959A1 (en) * | 2005-07-14 | 2007-01-25 | Myogen, Inc. | Use of inhibitors of the ubiquitin proteasome pathway for increasing contractility of the heart |
| WO2007047919A2 (en) * | 2005-10-20 | 2007-04-26 | University Of South Florida | Treatment of restenosis and stenosis with dasatinib |
| GB0609962D0 (en) | 2006-05-19 | 2006-06-28 | Biotica Tech Ltd | Novel compounds |
| US8283441B2 (en) * | 2006-10-31 | 2012-10-09 | University Of Toledo | Na+K+-ATPase-specific peptide inhibitors/activators of SRC and SRC family kinases |
| US20090143343A1 (en) | 2007-11-13 | 2009-06-04 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| EP2359813A1 (en) | 2010-02-04 | 2011-08-24 | Ratiopharm GmbH | Pharmaceutical composition comprising N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid |
| EP2988738A4 (en) * | 2013-01-10 | 2016-11-09 | Pulmokine Inc | THERAPEUTIC INDICATIONS OF KINASE INHIBITORS |
| AU2014287209B2 (en) * | 2013-07-09 | 2019-01-24 | Dana-Farber Cancer Institute, Inc. | Kinase inhibitors for the treatment of disease |
-
2016
- 2016-01-26 CN CN202110533185.2A patent/CN113244399A/zh active Pending
- 2016-01-26 US US15/544,401 patent/US10471059B2/en active Active
- 2016-01-26 MX MX2017009643A patent/MX2017009643A/es unknown
- 2016-01-26 JP JP2017539224A patent/JP6854766B2/ja active Active
- 2016-01-26 CA CA2974958A patent/CA2974958A1/en active Pending
- 2016-01-26 WO PCT/US2016/014882 patent/WO2016123086A1/en not_active Ceased
- 2016-01-26 EP EP25206316.9A patent/EP4653015A2/en active Pending
- 2016-01-26 CN CN201680018121.6A patent/CN107530298B/zh active Active
- 2016-01-26 HK HK18105513.7A patent/HK1245678A1/zh unknown
- 2016-01-26 EP EP16743949.6A patent/EP3250192B1/en active Active
-
2017
- 2017-07-25 MX MX2022012505A patent/MX2022012505A/es unknown
-
2019
- 2019-09-19 US US16/575,637 patent/US11458137B2/en active Active
-
2020
- 2020-12-02 JP JP2020200158A patent/JP2021050218A/ja active Pending
-
2022
- 2022-08-30 US US17/823,439 patent/US20230036788A1/en not_active Abandoned
-
2023
- 2023-02-03 JP JP2023015070A patent/JP2023052878A/ja active Pending
-
2024
- 2024-10-11 US US18/912,969 patent/US20250360129A1/en active Pending
-
2025
- 2025-01-16 JP JP2025005945A patent/JP2025061369A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018504416A5 (enExample) | ||
| JP2021050218A5 (enExample) | ||
| Zhao et al. | Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development | |
| EP3801524B1 (en) | Composition and method of treating cancer associated with egfr mutation | |
| AR094654A1 (es) | Modulador del receptor de andrógeno y sus usos, método para tratamiento, composición farmacéutica | |
| ES2734081T3 (es) | Apilimod para el uso en el tratamiento de melanoma | |
| US12336992B2 (en) | PAC-1 combination therapy | |
| EP3703755B1 (en) | Combination comprising at least one spliceosome modulator and at least one inhibitor chosen from bcl2 inhibitors, bcl2/bclxl inhibitors, and bclxl inhibitors for use in the treatment of cancer | |
| TWI873485B (zh) | 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案 | |
| KR20200128510A (ko) | 림프성 악성종양을 치료하는 방법 | |
| US20210346319A1 (en) | Pharmaceutical Compositions of R-(+)-Propranolol in Enantiomeric Excess and Therapeutic Uses Related Thereto | |
| US20160120871A1 (en) | Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent | |
| EP4615869A1 (en) | Combination therapy comprising bispecific antibodies comprising an nrp1 binding domain | |
| JP2025509278A (ja) | 小細胞肺癌を治療する方法 | |
| US11672812B2 (en) | Methods and compositions comprising tyrosine kinase inhibitor and triptolide for the treatment of cancer | |
| KR20220061147A (ko) | 눈 외양에 대한 익상편-관련 걱정을 경감하기 위한 방법 | |
| JP2025516647A (ja) | Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法 | |
| RU2849370C1 (ru) | Способы и схемы дозирования, содержащие ингибитор cdk2 и ингибитор cdk4, для лечения рака | |
| HK40068230A (en) | Methods for alleviating pterygium-associated worry about eye appearance | |
| WO2024176130A1 (en) | Tead- and her2-inhibitor combinations for treating cancer | |
| Popovic et al. | treatment of bipolar disorder | |
| Sánchez Gastaldo et al. | Targeted Therapies in Kidney Cancer | |
| Schimmel et al. | PKP-014 Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood samples | |
| Kang et al. | Targeted Cancer Therapy: Class Related Toxicities. | |
| HK1242204B (en) | Apilimod for use in the treatment of melanoma |